8:20 am Chair’s Opening Remarks

8:30 am IQ Consortium- Latest Developments & Challenges

  • Matthew Wagoner Associate Director - Mechanistic & Investigative Toxicology, Takeda

Synopsis

• Embedding the fundamentals of how 3D models have been utilized in the past 12
months and what are the latest challenges?
• Exploring how defining organotypic standards within specific platforms can
drive reproducibility
• Future directions and objectives

9:00 am Expertise Insight by Draper

  • Joe Charest Head of Business Development, Pharma R&D Technologies, Draper

9:30 am Panel Discussion: Regulatory & Industry Cross Talk – What are the Next Steps?

  • Suzanne Fitzpatrick Senior Advisor for Toxicology Center for Food Safety and Applied Nutrition , U.S Food and Drug Administration
  • Will Proctor Associate Director Investigative Toxicology, Genentech
  • Matthew Wagoner Associate Director - Mechanistic & Investigative Toxicology, Takeda

Synopsis

• Insight into how collaborations between regulators, academics and companies are driving
progress in 3D modeling
• Approaches to validating current MPS models
• Current requirements from the industry to improve model verification and success
• Discuss utilizing data exchange through smart compound libraries to assist with model standardisation

10:00 am Expertise Insight by Stemonix

10:30 am Speed Networking

11:00 am Morning Refreshments

Discovery Track

Utilizing 3D models to Increase Target & Drug Discovery

 

11:30 am Qualification & Implementation of Hepatic
Spheroids to Support Drug Discovery

• Comprehensive evaluation and qualification of hepatic
spheroid cultures for predicting clinical hepatotoxicity
retrospectively
• Considerations for positioning hepatic spheroid assays
during lead optimization and issue mitigation
• Advantages that 3D spheroid cultures have in relation
to traditional 2D hepatic models

Will Proctor, Associate Director, Investigative Toxicology,
Genentech

 

 

12:00 pm Non-Alcoholic Fatty Liver Disease (NAFLD) Drug
Discovery Through the Application of Quantitative
Systems Pharmacology & Microphysiology Systems

• Advantages of applying both high throughput and
biomimetic MPS for drug discovery
• Human liver biomimetic MPS disease model of NAFLD as
key experimental/mechanistic model to identify drugs
and drug combinations that halt/reverse
disease phenotypes
• Inference of pathways of disease progression based on
RNASeq of patient samples
• Computational prediction of drugs that target key pathways

Lans Taylor, Director - Drug Discovery Institute & Professor
- Allegheny Foundation, University of Pittsburgh

 

Development Track

12:30 pm Lunch

Screening Techniques to Increase Lead Optimization

1:30 pm High Throughput Cancer Spheroids for Drug
Screening

• Insight into the establishing an effective screening
compromise between complex matrix-based systems
and 2D systems

Matthew Lech, Senior Research Scientist, Pfizer

 

 

2:00 pm Turning Inherently Variable Cell-Based Assays
into Precision Tools for Drug Discovery in 3D - Case
Reports from Islet & Liver

Issue: High variability of native pancreatic islets makes
assay design complex and costly
Platform solution: Scalable formation of 3D microtissues
and automation compatible assays
Re-aggregated human 3D Islets – characterization
and functionality
Case study 1:
• Novel in vitro islet killing assay
• Detailed functional readouts in 3D
• Addition of external metabolic and immune stressors
Case study 2: Liver steatosis model using primary human
cells and lipid loading
Outlook: From 3D static assays to 3D microtissue-based
organ-on-a-chip devices under physiological
flow conditions

Matthius Von Herrath, Vice President, Novo Nordisk

 

 

2:30 pm Presentation Title to Be Announced Shortly

Prathap Kumar S. Mahalingaiah, Senior Scientist,
Investigative Toxicology & Pathology at AbbVie

 

 

3:00 pm Speaker Panel- Q & A Interactive Session

• Applying balance in spheroid studies of throughput with
model complexity
• How to overcome spheroid clustering to increase collation of
reliable results
• Insight into how quantitative systems pharmacology can assist
to interpret data to improve in vitro to in vivo translation

Enhancing Translatability & Stability in Model Development

3:30 pm Afternoon Tea

4:00 pm Roundtable Debate: Interactive Sessions Discussing the Key Challenges within 3D Landscape

Human Tissue Sourcing & Handling

Human Tissue Sourcing & Handling

• Discussing the role of industry wide best practices
for tissue handling guidelines to assist end users and
increase tissue quality for 3D model systems
• Discussing the development of quality control metrics
and minimum performance specifications to improve
quality assurance
• Advantages and limitations of current tissue biobanks

Janine McCarthy, Research Specialist, Physician’s
Committee for Responsible Medicine

Future Prospects: 3D Models in Regenerative Medicine & Cell Therapy
DEBATE- Accuracy of 3D Assays in Replacing In Vivo Models
DEBATE: Biomimetic Environment andImproving In Vitro-In Vivo Translation

5:00 pm Moderator Feedback: Roundtable Discussions & In Vitro-In Vivo Debate Outcome

5:15 pm Chair’s Closing Remarks

5:30 pm Poster Session

Synopsis

Continue to build your network during this interactive session presenting the latest data on 3D disease modelling, efficacy studies and target validation.